THE EFFCT OF METFORMIN USE ON PROGNOSIS IN PANCREATIC CANCER PATIENTS

Basit Öğe Kaydı
dc.contributor.authorEsbah, Onur
dc.contributor.authorEren, Tulay
dc.contributor.authorHelvaci, Kaan
dc.contributor.authorGuler, Tunc
dc.contributor.authorDuran, Ayse Ocak
dc.contributor.authorBal, Oznur
dc.contributor.authorOzdemir, Nuriye Yildirim
dc.date.accessioned2024-02-23T14:45:56Z
dc.date.available2024-02-23T14:45:56Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractBackground: Several clinical studies have shown the effect of mefformine on survival in pancreatic cancer. We aimed to evaluate whether the use of mefformin in diabetic pancreatic cancer patients provides a survival advantage or not. Methods: The data of 467 pancreatic adenocarcinoma patients diagnosed between 2003 and 2012 from five centers were analyzed, retrospectively. The groups were pancreatic cancer patients with diabetes who use metfonnin, who don't use metfornzin and non-diabetics. Results: Median overall survival was 8 months for the whole cohort, and 8 months for the group of non-diabetic patients. Overall survival was 8 months for the diabetic patients who use metfonnin whereas 10 months for the patients who do not use metformin. There was no statistically significant survival difference between the groups (p:0,76). Conclusion: Our study did not support clinical benefit of metformin in diabetic pancreatic cancer patients.en_US
dc.identifier.endpage471en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue2en_US
dc.identifier.startpage465en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17708
dc.identifier.volume30en_US
dc.identifier.wosWOS:000335937900029en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPancreatic Canceren_US
dc.subjectDiabetes Mellitusen_US
dc.subjectMetformineen_US
dc.titleTHE EFFCT OF METFORMIN USE ON PROGNOSIS IN PANCREATIC CANCER PATIENTSen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu